Patents by Inventor Robert Joseph Stagg

Robert Joseph Stagg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for treatment of cancer
    Patent number: 11339213
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly colorectal, ovarian (e.g., platinum-resistant ovarian), pancreatic, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., leucovorin, 5-fluorouracil, and irinotecan; paclitaxel; gemcitabine and ABRAXANE® (albumin-bound paclitaxel for injectable suspension); and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a colorectal, ovarian, pancreatic, or endometrial tumor.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 24, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar, Robert Joseph Stagg
  • Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
    Patent number: 10870693
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: December 22, 2020
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Robert Joseph Stagg, Steven Eugene Benner
  • METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
    Publication number: 20190023776
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly pancreatic, colorectal, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., gemcitabine and ABRAXANE®; leucovorin, 5-fluorouracil, and irinotecan; and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a pancreatic, colorectal, or endometrial tumor. Also described are methods of treating cancer, particularly pancreatic, colorectal, and endometrial cancer, comprising administering a therapeutically effect amount of an agent, antibody, or therapeutic combination of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 24, 2019
    Inventors: Jakob DUPONT, Hema PARMAR, Robert Joseph STAGG
  • THERAPEUTIC COMBINATION AND METHODS OF TREATMENT WTIH A DLL4 ANTAGONIST AND AN ANTI-HYPERTENSIVE AGENT
    Publication number: 20180346556
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Application
    Filed: April 30, 2018
    Publication date: December 6, 2018
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Robert Joseph STAGG, Steven Eugene Benner
  • Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
    Patent number: 9982042
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 29, 2018
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Robert Joseph Stagg, Steven Eugene Benner
  • Methods and Monitoring of Treatment With A DLL4 Antagonist
    Publication number: 20170299598
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Application
    Filed: February 1, 2017
    Publication date: October 19, 2017
    Inventors: Steven Eugene BENNER, Robert Joseph Stagg, Jakob Dupont
  • Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent
    Publication number: 20170166632
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Application
    Filed: October 27, 2016
    Publication date: June 15, 2017
    Inventors: Robert Joseph STAGG, Steven Eugene Benner
  • Methods and monitoring of treatment with a DLL4 antagonist
    Patent number: 9599620
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 21, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Steven Eugene Benner, Robert Joseph Stagg, Jakob Dupont
  • Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
    Patent number: 9511139
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: December 6, 2016
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Robert Joseph Stagg, Steven Eugene Benner
  • METHODS AND MONITORING OF TREATMENT WITH A DLL4 ANTAGONIST
    Publication number: 20160334423
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Application
    Filed: March 15, 2016
    Publication date: November 17, 2016
    Inventors: Steven Eugene BENNER, Robert Joseph Stagg, Jakob Dupont
  • Methods for Treating Cancer with DLL4 Antagonists
    Publication number: 20160324961
    Abstract: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a DLL4 antagonist.
    Type: Application
    Filed: April 13, 2016
    Publication date: November 10, 2016
    Inventors: Robert Joseph STAGG, Steven Eugene BENNER, John LEWICKI, Timothy Charles HOEY
  • METHODS OF TREATING NEUROENDOCRINE TUMORS USING FRIZZLED-BINDING AGENTS
    Publication number: 20160235844
    Abstract: Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a Wnt antagonist. In one embodiment, the Wnt antagonist is an anti-FZD antibody. In another embodiment, the Wnt antagonist is a soluble FZD receptor polypeptide. In a further embodiment, the Wnt antagonist is an anti-Wnt antibody.
    Type: Application
    Filed: January 12, 2016
    Publication date: August 18, 2016
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Robert Joseph Stagg, Jakob Dupont
  • Methods of treating neuroendocrine tumors using frizzled-binding agents
    Patent number: 9266959
    Abstract: Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a Wnt antagonist. In one embodiment, the Wnt antagonist is an anti-FZD antibody. In another embodiment, the Wnt antagonist is a soluble FZD receptor polypeptide. In a further embodiment, the Wnt antagonist is an anti-Wnt antibody.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: February 23, 2016
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Robert Joseph Stagg, Jakob Dupont
  • Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent
    Publication number: 20150118232
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: April 30, 2015
    Inventors: Robert Joseph Stagg, Steven Eugene Benner
  • Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
    Patent number: 8883145
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: November 11, 2014
    Assignee: Oncomed Pharmaceuticals, Inc.
    Inventors: Robert Joseph Stagg, Steven Eugene Benner
  • Methods and Monitoring of Treatment with a DLL4 Antagonist
    Publication number: 20140227252
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Application
    Filed: October 31, 2013
    Publication date: August 14, 2014
    Applicant: ONCOMED PHARMACEUTICALS , INC.
    Inventors: STEVEN EUGENE BENNER, ROBERT JOSEPH STAGG, JAKOB DUPONT
  • Methods and Monitoring of Treatment with a DLL4 Antagonist
    Publication number: 20140220001
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Application
    Filed: October 31, 2013
    Publication date: August 7, 2014
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Steven Eugene BENNER, Robert Joseph Stagg, Jakob Dupont
  • METHODS OF TREATING NEUROENDOCRINE TUMORS USING FRIZZLED-BINDING AGENTS
    Publication number: 20140134159
    Abstract: Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a Wnt antagonist. In one embodiment, the Wnt antagonist is an anti-FZD antibody. In another embodiment, the Wnt antagonist is a soluble FZD receptor polypeptide. In a further embodiment, the Wnt antagonist is an anti-Wnt antibody.
    Type: Application
    Filed: October 22, 2013
    Publication date: May 15, 2014
    Applicant: ONCOMED PHARMACEUTICALS, INC.
    Inventors: ROBERT JOSEPH STAGG, JAKOB DUPONT
  • METHODS FOR TREATING CANCER WITH DLL4 ANTAGONISTS
    Publication number: 20130323265
    Abstract: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a DLL4 antagonist.
    Type: Application
    Filed: November 15, 2011
    Publication date: December 5, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Robert Joseph Stagg, Steven Eugene Benner, John Lewicki, Timothy Charles Hoey
  • Therapeutic Combination and Methods of Treatment With a DLL4 Antagonist and an Anti-Hypertensive Agent
    Publication number: 20120263721
    Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
    Type: Application
    Filed: October 18, 2010
    Publication date: October 18, 2012
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Robert Joseph Stagg, Steven Eugene Benner